{"id":5712,"date":"2026-10-14T08:21:03","date_gmt":"2026-10-14T02:51:03","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/sunpharma-share-price-today-2026-10-14\/"},"modified":"2026-10-14T08:21:05","modified_gmt":"2026-10-14T02:51:05","slug":"sunpharma-share-price-today-2026-10-14","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/sunpharma-share-price-today-2026-10-14\/","title":{"rendered":"Sun Pharma in Focus After NCD Issuance Approval and Director Resignation | 14 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"premarket\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: SUNPHARMA<\/strong> \u00b7 14 October 2026 \u00b7 Pre-market update<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Previous close<\/div>\n<div>\u20b91,760.00<\/div>\n<\/div>\n<div>\n<div>Previous day change<\/div>\n<div>+0.00%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b91,776.60 \/ \u20b91,750.00<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>11.42 lakh<\/div>\n<\/div>\n<div>\n<div>Previous trading day<\/div>\n<div>12 October 2026<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Sun Pharmaceutical Industries is in focus ahead of the market open following its board&#x27;s approval to raise up to INR 10,000 crore via non-convertible debentures and the assignment of &#x27;CRISIL AAA\/Stable&#x27; and &#x27;[ICRA]AAA (Stable)&#x27; ratings to the proposed NCD programme. Additionally, the company reported the resignation of Non-Executive Independent Director Gautam Doshi effective October 12, 2026.<\/li>\n<li>Sun Pharmaceutical Industries announced that its board of directors approved the issuance of listed, rated, unsecured, redeemable non-convertible debentures on a private placement basis for an aggregate amount not exceeding INR 10,000 crore. CRISIL and ICRA subsequently assigned &#x27;AAA\/Stable&#x27; ratings to the proposed NCD programme while reaffirming existing credit facilities.<\/li>\n<li>Trading volume was 0.71 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Sun Pharmaceutical Ind L Company News Before Market Open<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Sun Pharmaceutical Industries is in focus ahead of the market open following its board&#x27;s approval to raise up to INR 10,000 crore via non-convertible debentures and the assignment of &#x27;CRISIL AAA\/Stable&#x27; and &#x27;[ICRA]AAA (Stable)&#x27; ratings to the proposed NCD programme. Additionally, the company reported the resignation of Non-Executive Independent Director Gautam Doshi effective October 12, 2026.<\/p>\n<p class=\"wt-copy\">The board-approved INR 10,000 crore NCD issuance signals major fundraising plans that will shape the company&#x27;s capital structure. Top-tier credit ratings (&#x27;CRISIL AAA\/Stable&#x27; and &#x27;[ICRA]AAA (Stable)&#x27;) assigned to the proposed NCD programme reflect strong underlying business and financial profiles. The departure of independent director Gautam Doshi marks a notable board-level transition following the October 12 meeting.<\/p>\n<p class=\"wt-copy\">11.42 lakh shares traded on 12 October 2026. This compares with a 20-day average daily volume of 16.12 lakh shares (0.71 times). The five-day average daily volume was 13.74 lakh shares.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Company-specific context<\/div>\n<div class=\"wt-card-body\"><strong>NCD Issuance and Director Resignation<\/strong><\/p>\n<p class=\"wt-copy\">The board-approved INR 10,000 crore NCD issuance signals major fundraising plans that will shape the company&#x27;s capital structure. Top-tier credit ratings (&#x27;CRISIL AAA\/Stable&#x27; and &#x27;[ICRA]AAA (Stable)&#x27;) assigned to the proposed NCD programme reflect strong underlying business and financial profiles. The departure of independent director Gautam Doshi marks a notable board-level transition following the October 12 meeting.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Board Approves Non-Convertible Debenture Issuance up to INR 10,000 Crore<\/div>\n<div class=\"wt-card-date\">12 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Sun Pharmaceutical Industries announced that its board of directors approved the issuance of listed, rated, unsecured, redeemable non-convertible debentures on a private placement basis for an aggregate amount not exceeding INR 10,000 crore. CRISIL and ICRA subsequently assigned &#x27;AAA\/Stable&#x27; ratings to the proposed NCD programme while reaffirming existing credit facilities.<\/p>\n<p class=\"wt-copy\">Debt-funding initiatives and credit rating assessments are key considerations for monitoring the company&#x27;s capital structure and upcoming financial obligations.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Resignation of Non-Executive Independent Director Gautam Doshi<\/div>\n<div class=\"wt-card-date\">12 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Gautam Doshi tendered his resignation as a Non-Executive, Independent Director of the company with effect from October 12, 2026, citing personal commitments and confirming no other material reasons for his departure.<\/p>\n<p class=\"wt-copy\">Changes in board composition and departures of independent directors draw investor attention regarding corporate governance.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Outcome of Board Meeting<\/div>\n<div class=\"wt-card-date\">13 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Outcome of the Board Meeting held on 12 October 2026<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/SUNSEC_12102026195625_BMOutcome12October2026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 June 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">54.48%<\/div>\n<div class=\"wt-note\">54.48% on 31 March 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">14.53%<\/div>\n<div class=\"wt-note\">15.93% on 31 March 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">36.71%<\/div>\n<div class=\"wt-note\">37.04% on 31 March 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1694893_17072026122439_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 12.84% on 30 June 2026. This compares with 11.96% on 31 March 2026, a change of +0.88 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 49 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Icici Prudential Value Fund<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">8.92 crore shares \u00b7 3.72%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Sbi Nifty 50 Etf<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">5.67 crore shares \u00b7 2.36%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Nippon Life India Trustee Ltd-A\/C Nippon India Large Cap Fund<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">3.31 crore shares \u00b7 1.38%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1694893_17072026122439_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>Historical Bulk \/ Block Deals<\/h2>\n<div class=\"wt-grid wt-grid-cards\">\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">The Mtbj Ltd. As Trst For Govrnmnt Pension Invstmnt Fund Mutb400045794<\/div>\n<div class=\"wt-card-date\">24 June 2026<\/div>\n<div class=\"wt-card-body\">Buy \u00b7 1.54 lakh shares \u00b7 \u20b91,868.00<\/p>\n<div class=\"wt-note wt-source-note\">Public market-data page<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">The Mtbj Ltd. As Trst For Govrnmnt Pension Invstmnt Fund Mtbj400045828<\/div>\n<div class=\"wt-card-date\">24 June 2026<\/div>\n<div class=\"wt-card-body\">Sell \u00b7 1.54 lakh shares \u00b7 \u20b91,868.00<\/p>\n<div class=\"wt-note wt-source-note\">Public market-data page<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Market reaction to the newly announced INR 10,000 crore NCD issuance framework after the open.<\/li>\n<li>Trading volume relative to the prior session&#x27;s 11,41,685 shares and movement around the previous close of 1760.0.<\/li>\n<li>Technical levels near the 20-day average close of 1824.04 and the recent 20-day low of 1745.0.<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/sunpharma-share-price-today-2026-10-13\/\">Sun Pharma in Focus After INR 10,000 Crore NCD Approval and Director Resignation | 13 October 2026 \u2014 13 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/sunpharma-share-price-today-2026-10-07\/\">Sun Pharmaceutical Ind L Share Price Today: Why SUNPHARMA Is Falling 1.28% | 7 October 2026 \u2014 7 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/sunpharma-share-price-today-2026-09-30\/\">Why Sun Pharma Shares Fell 2.60% Today Amid Pharma Sector Weakness | 30 September 2026 \u2014 30 September 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/sunpharma\/\">More Sun Pharmaceutical Ind L news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Sun Pharmaceutical Ind L company news?<\/h3>\n<p class=\"wt-copy\">Sun Pharmaceutical Industries announced that its board of directors approved the issuance of listed, rated, unsecured, redeemable non-convertible debentures on a private placement basis for an aggregate amount not exceeding INR 10,000 crore. CRISIL and ICRA subsequently assigned &#x27;AAA\/Stable&#x27; ratings to the proposed NCD programme while reaffirming existing credit facilities.<\/p>\n<h3>How strong was Sun Pharmaceutical Ind L\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">11.42 lakh shares traded, 0.71 times the 20-day average daily volume. The price and volume data are dated 12 October 2026.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/sunpharma-share-price-today-2026-10-14\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/sunpharma-share-price-today-2026-10-14\/\"}, \"headline\": \"Sun Pharma in Focus After NCD Issuance Approval and Director Resignation | 14 October 2026\", \"description\": \"Sun Pharmaceutical Industries in pre-market focus after board approves up to INR 10,000 crore NCD issuance, secures top credit ratings, and notes director.\", \"datePublished\": \"2026-10-14T08:20:54.352510+05:30\", \"dateModified\": \"2026-10-14T08:20:54.352510+05:30\", \"author\": {\"@type\": \"Organization\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"reviewedBy\": {\"@type\": \"Person\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"WittyTrades\", \"url\": \"https:\/\/www.wittytrades.com\/\"}, \"inLanguage\": \"en-IN\", \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/sunpharma-company-news-2026-10-14.jpg\"]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Credit Rating\",\"summary\":\"Credit Rating\",\"source\":\"NSE\",\"published\":\"13-Oct-2026 17:54:34\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SUNSEC_13102026175414_Intimation_to_SE_-_NCDs_Credit_Ratings.pdf\",\"disclosure_text\":\"Sun Pharmaceutical Industries Limited SUN HOUSE, Plot No. 201 B\/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 Website: www.sunpharma.com Email: secretarial@sunpharma.com CIN: L24230GJ1993PLC019050 Registered Office: SPARC, Tandalja, Vadodara \u2013 390 012, Gujarat, INDIA Reaching People. Touching Lives 13 October 2026 National Stock Exchange of India Limited BSE Limited Scrip Symbol: SUNPHARMA Scrip Code: 524715 Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 \u2013 Update on Credit Ratings Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that CRISIL Ratings Limited (\\\"CRISIL\\\") and ICRA Limited (\\\"ICRA\\\") have assigned ratings to the proposed Non-Convertible Debenture (\\\"NCD\\\") programme of Sun Pharmaceutical Industries Limited (\\\"Company\\\") and reaffirmed the ratings assigned to the existing facilities of the Company. The details of the ratings are set out below: Rating Agency Instrument\/Type Rating CRISIL Non-Convertible Debentures Crisil AAA\/Stable (Assigned) Commercial Paper Crisil A1+ (Reaffirmed) Long Term Rating Crisil AAA\/Stable (Reaffirmed) Short Term Rating Crisil A1+ (Reaffirmed) ICRA Non-Convertible Debentures [ICRA]AAA (Stable) assigned Commercial Paper [ICRA]A1+ reaffirmed Long-term short-term, fund-based\/ non- fund-based limits [ICRA]AAA (Stable)\/ [ICRA]A1+ reaffirmed As stated in the respective rating communications, the ratings factor in, inter alia, the Company's strong business and financial profile and also take into consideration the proposed acquisition of Organon & Co. by the Company. Further, ICRA has reaffirmed its rating of [ICRA]A1+ reaffirmed to the short-term fund-based\/non-fund- based facilities aggregating INR 150 crore of Sun Pharma Laboratories Limited (\\\"SPLL\\\"), a wholly-owned subsidiary of the Company. Copies of the rating rationales issued by CRISIL and ICRA in respect of the Company and by ICRA in respect of SPLL are enclosed as Annexure A, Annexure B and Annexure C, respectively. Fo r Sun Pharmaceutical Industries Limited (Anoop Deshpande) Company Secretary and Compliance Officer ICSI Membership No.: A23983 Rating Rationale October 13, 2026 | Mumbai Sun Pharmaceutical Industries Limited 'Crisil AAA\/Stable' assigned to non-convertible debentures Rating Action Total Bank Loan Facilities Rated Rs.176 Crore Regulator OfInstrument Long Term Rating Crisil AAA\/Stable (Reaffirmed) RBI Short Term Rating Crisil A1+ (Reaffirmed) RBI Instrument Ratings Regulator OfInstrument Rs.15000 Crore Non Convertible Debentures Crisil AAA\/Stable (Assigned) SEBI Rs.4000 Crore Commercial Paper Crisil A1+ (Reaffirmed) RBI Note: None of the Directors on Crisil Ratings Limited\u2019s Board are members of rating committee and thus do not participate in discussion or assignment of any ratings. The Board of Directors also does not discuss any ratings at its meetings. 1 crore = 10 million Refer to Annexure for Details of Instruments & Bank Facilities Detailed Rationale Crisil Ratings has assigned its \u2018Crisil AAA\/Stable\u2019 rating to the proposed non-convertible debentures of Sun Pharmaceutical Industries Limited (Sun Pharma) and has reaffirmed its \u2018Crisil AAA\/Stable\/Crisil A1+\u2019 ratings on the existing bank facilities and commercial paper programme. The ratings continue to reflect the leadership position of Sun Pharma in the domestic formulations segment, its strong presence in the US and other regulated markets with a robust specialty products portfolio and strong financial risk profile. These strengths are partially offset by exposure to regulatory risk and susceptibility to intense competition and US policy uncertainties. Operating performance remained healthy in the first quarter of fiscal 2027, with operating income increasing by around 10% on-year to Rs 15,300 crore, driven by strong growth in the India formulations and global innovative medicines businesses. India formulations sales grew 16% on-year to Rs 5,475 crore, while global innovative medicines sales increased 13% to $351 million and constituted around 22% of consolidated sales; this was partly offset by a 10% decline in US formulations sales amid continued weakness in the generics business. Operating profit increased 2.7% to Rs 4,418 crore, though operating margin moderated to 29% from 31.1% in the corresponding period of the previous fiscal. Nevertheless, operating profitability remained healthy, supported by a favourable product mix and increasing contribution from the innovative medicines\u2019 portfolio. Earlier, Sun Pharma\u2019s consolidated revenue grew 12% on-year in fiscal 2026 driven by healthy growth in the domestic, emerging and rest-of-the-world markets and ramp-up in the sale of innovative medicine products amid subdued growth in the US formulations market, and the operating margin was healthy at 30.5% (29.3% in fiscal 2025) supported by a favourable product mix. Crisil Ratings expects revenue to grow at a high single-digit rate annually over the medium term, supported by the scale-up of the innovative medicines portfolio, including the recently launched Leqselvi and UNLOXYCT, and steady growth across other key markets. Operating margin is expected to r emain healthy at 26-27% over this period, notwithstanding sizeable research and development (R&D) spend of 6-8% of revenue and upfront marketing and commercialisation expenses for innovative medicines ahead of commensurate revenue scale-up. While Sun Pharma\u2019s agreement with the US administration provides some mitigation against tariff-related risks for a two-year period, after which the arrangement is subject to review, the evolving policy environment in the US, particularly implementation of Most Favoured Nation (MFN)-linked drug pricing measures and tariffs on pharmaceutical products, and their consequent impact on realisations and operating profitability, will remain monitorable. Earlier, Sun Pharma had announced on April 27, 2026, the proposed acquisition of US-based Organon & Co. (Organon; rated \u2018BB\/CreditWatch Positive\/A-4\u2019 by S&P Global Ratings) for an enterprise value of $11.75 billion. Organon, a global healthcare company spun off from Merck, reported revenue of $6.2 billion and adjusted operating p rofit of around $2 billion in calendar year 2025, translating into a healthy operating margin of around 31%. During the first half of calendar year 2026, revenue remained broadly stable on-year over $3 billion, while operating margin sustained around 30%. Established brands accounted for around 60% of revenue during the period, followed by innovative medicines in women\u2019s health at 27% and biosimilars at 13%. 10\/13\/26, 2:36 PM Rating Rationale https:\/\/www.crisilratings.com\/mnt\/winshare\/Ratings\/RatingList\/RatingDocs\/SunPharmaceuticalIndustriesLimited_October 13_ 2026_RR_405525.\u2026 1\/11 Annexure A The acquisition should significantly strengthen Sun Pharma\u2019s global scale and diversify its busines s profile across therapies, products and geographies. On consummation, the combined entity is expected to rank among the top 25 global pharmaceutical companies, with pro-forma revenue of around $12.4 billion. The transaction will provide Sun Pharma with an established presence in women\u2019s health and biosimilars, expand its geographical reach and further strengthen its innovative medicines portfolio. On a pro-forma basis, established brands and branded generics are expected to constitute around 51% of consolidated revenue, followed by innovative medicines at 27%, generics at 15%, biosimilars at 6%, and active pharmaceutical ingredients (APIs) and others at 2%. Operating profitability is expected to remain healthy, with earnings before interest, tax, depreciation and amortisation (Ebitda) margin of 28-30%, translating into operating profit of around $4 billion and supporting healthy annual cash generation. Crisil Ratings believes the acquisition provides a strong strategic fit and should strengthen Sun Pharma\u2019s business risk profile, though the sizeable transaction will result in a temporary increase in leverage. The transaction has received approval from Organon\u2019s shareholders and is expected to be completed over late 2026 and early 2027, subject to requisite regulatory approvals across relevant jurisdictions. Integration risks arising from the scale and geographical spread of Organon\u2019s operations are expected to be mitigated by a structured implementation plan and management oversight. Nevertheless, timely integration of operations, realisation of envisaged business synergies, and the evolution of contingent liabilities and regulatory matters will remain key monitorables. The financial risk profile is expected to moderate temporarily following the acquisition but should remain supported by strong cash generation and subsequent deleveraging. Sun Pharma is expected to deploy $2.0-2.5 billion of its cash surplus and internal accruals towards the acquisition, with the balance funded through additional debt of $9.5-10.0 billion. Consequently, leverage is expected to increase materially immediately following the transaction, with net debt to Ebitda estimated at 1.5-2.0 times in fiscal 2028, the first full year of operations post-acquisition. However, healthy cash accrual generation from the combined business should support sizeable debt reduction thereafter, consistent with the management\u2019s stated philosophy of maintaining a debt-light balance sheet. The financial risk profile remained strong, as reflected in robust adjusted networth of over Rs 71,000 crore as on March 31, 2026, moderate debt (including lease liabilities) of Rs 4,627 crore (Rs 2,362 crore as on March 31, 2025) and sizeable cash surplus of over Rs 30,000 crore as on March 31, 2026. Analytical Approach Crisil Ratings has combined the business and financial risk profiles of Sun Pharma and its various subsidiaries, joint ventures (JVs) and associates, collectively known as Sun Pharma, as these entities have considerable operational and financial linkages. For JVs and associates, a moderate integration approach is followed \u2014 Crisil Ratings factors in the share of profit from JVs, as also any incremental investment required by them. Intangibles (such as brands and trademarks) and goodwill on consolidation have also been amortised over five years. Please refer Annexure - List of entities consolidated, which captures the list of entities considered and their analytical treatment of consolidation. Key Rating Drivers - Strengths Leadership position in domestic formulations Sun Pharma is the leader in the domestic formulations segment (contributed 33% to revenue in fiscal 2026) with a market share of ~8.5% as on June 30, 2026 (source: All India Organisation of Chemists and Druggists MAT Data for June 2026). Its leading position in the chronic segment is backed by specialisation in technically complex products, strong brand equity and large product portfolio. Sun Pharma has 31 brands among the top 300 brands in the domestic market. It also ranks among the top 10 consumer healthcare companies in India and enjoys strong brand equity for key products such as Revital (vitamin and mineral supplement) and Volini (pain reliever). These brands give it a competitive edge and have helped lay the foundation for the global over-the-counter (OTC) business. Sun Pharma sells OTC products in over 20 international markets. Its key therapeutic areas in domestic formulations are neuropsychiatry, cardiology, gastroenterology, pain-analgesics and anti- infectives. The company continues to enjoy a dominant position in these segments. Strong presence in the US and other regulated markets with robust specialty products portfolio The US, which contributed around 27% to revenue in first quarter of fiscal 2027 (29% in fiscal 2026), is among the key geographies for Sun Pharma. The company ranks 13th among the generic pharmaceutical companies in the US. It has a robust product pipeline and had filed 677 abbreviated new drug applications (ANDAs) and 70 new drug applications (NDAs ) of which 119 ANDAs and 13 NDAs were pending approval from the US Food and Drug Administration (FDA) as on June 30, 2026. With extensive R&D over the past several years, Sun Pharma has established a robust portfolio of innovative medicine products in the US and other regulated markets. The successful launch and commercialisation of Deuruxolitinib (Leqselvi) in July 2025 and UNLOXYCT (through Sun Pharma\u2019s acquisition of Checkpoint) in January 2026 is expected to further strengthen innovative medicine produc t offerings over the medium term. Healthy market position in the other regulated markets of Europe, Japan, Canada and Australia is supported by the company\u2019s strength in the innovative medicines, generic and OTC segments. Strong financial risk profile Driven by a healthy adjusted networth and moderate debt, adjusted gearing was low at 0.06 time as on March 31, 2026. Large cash accrual will suffice to cover moderate organic capital expenditure (capex\u2014including the greenfield capex) and incremental working capital requirement. Debt protection metrics were healthy with adjusted interest coverage ratio above 50 times for fiscal 2026. While gross debt (including lease liabilities) increased to ~Rs 4,627 crore as on March 31, 2026, following the debt availed for funding Checkpoint Therapeutics acquisition, the financial risk profile will undergo a transition due to the Organon transaction. The acquisition is expected to be largely debt-funded, involving $9.5\u201310 billion in committed bank financing (including the expected takeover of Organon\u2019s existing debt of ~$8.5 billion). Crisil Ratings expects the leverage to increase with net debt\/Ebitda of 1.5\u20132.0 times in fiscal 2028 (the first full year post-acquisition). However, the financial risk profile is expected to 10\/13\/26, 2:36 PM Rating Rationale https:\/\/www.crisilratings.com\/mnt\/winshare\/Ratings\/RatingList\/RatingDocs\/SunPharmaceuticalIndustriesLimited_October 13_ 2026_RR_405525.\u2026 2\/11 remain healthy, supported by a significant scale-up in business, strong operating profitability of 28-30%, and combined annual Ebitda of $3.8-4.0 billion. The company is expected to de-lever over the medium term in line with its conservative leverage philosophy. While large cash flow and sizeable liquid surplus will ensure strong financial flexibility, any further substantial, debt- funded capex will be monitorable. Key Rating Drivers - Weaknesses Exposure to regulatory risk Sun Pharma faces regulatory risk with instances of adverse observations for its plants. In December 2022, the US FDA issued an import alert for the company\u2019s facility in Halol, Gujarat. Following this, the company also received a warning letter about its facilities at Dadra and Mohali and the facility at Baska was classified as Official Action Initiated (OAI) by US FDA. This will impact sales of the facilities until non-compliances are resolved. Four of its facilities (at Taonsa, Karkhadi, Paonta Sahib and Dewas) continue to be subject to certain provisions of the consent decree of permanent injunction. Resolution of pending regulatory issues and sustained compliance remain monitorable. Crisil Ratings notes that Sun Pharma has provided for sizeable settlement amounts historically and continues to make proportionate provisions factoring the on-going litigations and tax liabilities under dispute, the impact of which may not be ascertainable at present. Higher-than-expected movement in such provisions, settlements or any adverse regulatory outcomes materially impacting cash surplus would be monitorable. Susceptibility to intense competition and US policy uncertainties Sun Pharma faces intense competition in the US generics market with the introduction of authorised generics, customer consolidation, faster pace of ANDA approvals by the US FDA, and healthcare cost-containment measures by the US government. Also, players in the US and Europe remain vulnerable to pricing pressure on account of entry of several cost- competitive Indian players. Increasing competition in the international markets and R&D cost could constrain the operating margin. However, risks from potential US tariffs remain monitorable. Sun Pharma\u2019s agreement with the US administration to supply its Medicaid portfolio at lower prices provides some mitigation against tariff-related risks for a two-year period, after which the arrangement is subject to review. Furthermore, uncertainty around potential US tariffs for the generics portfolio, which is currently exempt from tariffs, will remain a key monitorable. Liquidity Superior Crisil Ratings expects Sun Pharma\u2019s annual cash accrual (excluding Organon) of Rs 9,000-10,000 crore to be sufficient to cover near-term debt obligation and incremental working capital requirement. Organic capex is expected to remain moderate at Rs 2,000-2,500 crore annually along with the announced greenfield capex of Rs 3,000 crore and is likely to be funded through cash accrual and liquid surplus. Liquid surplus was strong above Rs 30,000 crore as on March 31, 2026. Post the Organon acquisition, Crisil Ratings expects combined annual cash accruals to increase significantly to Rs 22,000\u2013 25,000 crore, providing ample cushion to cover large part of debt obligations, incremental working capit al, and organic capex. Consolidated capex, including the Madhya Pradesh greenfield project and routine maintenance, will be largely funded through internal accruals. Financial flexibility is further enhanced by access to unutilised bank lines. As per current repayment schedule, Organon has $3.5 billion of debt obligation maturing in calendar year 2028, which may require part refinancing, should a substantial portion not be prepaid earlier. Any significant payout towards legal or regulatory claim settlements or further large acquisition will remain monitorable. ESG Profile Crisil Rat\"},{\"title\":\"Resignation of Director\/KMP\/SMP\",\"summary\":\"Resignation of Director\/KMP\/SMP\",\"source\":\"NSE\",\"published\":\"12-Oct-2026 20:34:43\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SUNPHARMA_ROID_100278_KMP_Doc.zip\",\"disclosure_text\":\"\"},{\"title\":\"Resignation\",\"summary\":\"Resignation of Director of the Company\",\"source\":\"NSE\",\"published\":\"12-Oct-2026 20:05:00\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SUNSEC_12102026200413_BMOutcome12October2026.pdf\",\"disclosure_text\":\"Sun Pharmaceutical Industries Limited SUN HOUSE, Plot No. 201 B\/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 Website: www.sunpharma.com Email: secretarial@sunpharma.com CIN: L24230GJ1993PLC019050 Registered Office: SPARC, Tandalja, Vadodara \u2013 390 012, Gujarat, INDIA Reaching People. Touching Lives 12 October 2026 National Stock Exchange of India Limited BSE Limited NSE Code: SUNPHARMA BSE Code: 524715 Outcome of the Board Meeting held today, i.e., 12 October 2026 F urther to the communication dated 07 October 2026, this is to inform that the meeting of the Board of Directors of the Company (\u201cBoard\u201d) was held today, i.e. 12 October 2026, which commenced at 05:00 P.M. and concluded at 05:50 P.M., IST. The Board, inter alia, considered and approved the following: 1. Issuance of Non-Convertible Debentures T he Board of Directors has approved the issuance of listed, rated, unsecured, redeemable non- convertible debentures (\\\"NCDs\\\"), on a private placement basis, in one or more tranches and\/or series, for an aggregate amount not exceeding INR 10,000 Crore. T he Board has also approved the related issuance framework and authorised the Finance Committee to determine and approve the tranche-specific terms and conditions of the NCDs, including matters relating to their issuance, allocation and allotment, within the framework approved by the Board. T he disclosures required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 shall be made at the appropriate stage, upon issuance and\/or allotment of the NCDs. 2. Resignation of Mr. Gautam Doshi M r. Gautam Doshi (DIN: 00004612) has tendered his resignation as a Non-Executive, Independent Director of the Company with effect from 12 October 2026, citing personal reasons. He has confirmed that there are no material re asons for his resignation other than those stated in his resignation letter. Consequent upon his resignation, he has also ceased to hold positions on the Committees of the Board of Directors of the Company. T he Board of Directors has taken note of the resignation of Mr. Gautam Doshi and placed on record its sincere appreciation for the valuable guidance and contributions made by him during his tenure as an Independent Director of the Company. The details required under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are provided in Annexure A and the resignation letter of Mr. Gautam Doshi is enclosed herewith as Annexure B. Fo r Sun Pharmaceutical Industries Limited ( Anoop Deshpande) Company Secretary and Compliance Officer ICSI Membership No.: A23983 Sun Pharmaceutical Industries Limited SUN HOUSE, Plot No. 201 B\/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 Website: www.sunpharma.com Email: secretarial@sunpharma.com CIN: L24230GJ1993PLC019050 Registered Office: SPARC, Tandalja, Vadodara \u2013 390 012, Gujarat, INDIA Reaching People. Touching Lives Annexure A D isclosure under Para (A) of Part (A) of Schedule III to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 Sr. No. Particulars 1 Name Mr. Gautam Doshi (DIN: 00004612) 2 Reason for change viz. resignation Resignation from the position of Non - Executive Independent Director of the Company with immediate effect due to his personal commitments. 3 Date of cessation 12 October 2026 4 Brief profile (in case of appointment); Not Applicable 5 Disclosure of relationships between directors (in case of appointment of a director) Not Applicable 6 Letter of resignation along with detailed reason for resignation Enclosed as Annexure B 7. Names of listed entities in which the resigning director holds directorships, indicating the category of directorship and membership of board committees, if any Not Applicable 8. The independent director shall, along with the detailed reasons, also provide a confirmation that there are no other material reasons other than those provided Mr. Gautam Doshi confirmed that there are no material reasons for his resignation other than those mentioned in her resignation letter. Annexure B\"},{\"title\":\"Outcome of Board Meeting\",\"summary\":\"Outcome of the Board Meeting held on 12 October 2026\",\"source\":\"NSE\",\"published\":\"12-Oct-2026 19:57:07\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SUNSEC_12102026195625_BMOutcome12October2026.pdf\",\"disclosure_text\":\"Sun Pharmaceutical Industries Limited SUN HOUSE, Plot No. 201 B\/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 Website: www.sunpharma.com Email: secretarial@sunpharma.com CIN: L24230GJ1993PLC019050 Registered Office: SPARC, Tandalja, Vadodara \u2013 390 012, Gujarat, INDIA Reaching People. Touching Lives 12 October 2026 National Stock Exchange of India Limited BSE Limited NSE Code: SUNPHARMA BSE Code: 524715 Outcome of the Board Meeting held today, i.e., 12 October 2026 F urther to the communication dated 07 October 2026, this is to inform that the meeting of the Board of Directors of the Company (\u201cBoard\u201d) was held today, i.e. 12 October 2026, which commenced at 05:00 P.M. and concluded at 05:50 P.M., IST. The Board, inter alia, considered and approved the following: 1. Issuance of Non-Convertible Debentures T he Board of Directors has approved the issuance of listed, rated, unsecured, redeemable non- convertible debentures (\\\"NCDs\\\"), on a private placement basis, in one or more tranches and\/or series, for an aggregate amount not exceeding INR 10,000 Crore. T he Board has also approved the related issuance framework and authorised the Finance Committee to determine and approve the tranche-specific terms and conditions of the NCDs, including matters relating to their issuance, allocation and allotment, within the framework approved by the Board. T he disclosures required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 shall be made at the appropriate stage, upon issuance and\/or allotment of the NCDs. 2. Resignation of Mr. Gautam Doshi M r. Gautam Doshi (DIN: 00004612) has tendered his resignation as a Non-Executive, Independent Director of the Company with effect from 12 October 2026, citing personal reasons. He has confirmed that there are no material re asons for his resignation other than those stated in his resignation letter. Consequent upon his resignation, he has also ceased to hold positions on the Committees of the Board of Directors of the Company. T he Board of Directors has taken note of the resignation of Mr. Gautam Doshi and placed on record its sincere appreciation for the valuable guidance and contributions made by him during his tenure as an Independent Director of the Company. The details required under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are provided in Annexure A and the resignation letter of Mr. Gautam Doshi is enclosed herewith as Annexure B. Fo r Sun Pharmaceutical Industries Limited ( Anoop Deshpande) Company Secretary and Compliance Officer ICSI Membership No.: A23983 Sun Pharmaceutical Industries Limited SUN HOUSE, Plot No. 201 B\/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 Website: www.sunpharma.com Email: secretarial@sunpharma.com CIN: L24230GJ1993PLC019050 Registered Office: SPARC, Tandalja, Vadodara \u2013 390 012, Gujarat, INDIA Reaching People. Touching Lives Annexure A D isclosure under Para (A) of Part (A) of Schedule III to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 Sr. No. Particulars 1 Name Mr. Gautam Doshi (DIN: 00004612) 2 Reason for change viz. resignation Resignation from the position of Non - Executive Independent Director of the Company with immediate effect due to his personal commitments. 3 Date of cessation 12 October 2026 4 Brief profile (in case of appointment); Not Applicable 5 Disclosure of relationships between directors (in case of appointment of a director) Not Applicable 6 Letter of resignation along with detailed reason for resignation Enclosed as Annexure B 7. Names of listed entities in which the resigning director holds directorships, indicating the category of directorship and membership of board committees, if any Not Applicable 8. The independent director shall, along with the detailed reasons, also provide a confirmation that there are no other material reasons other than those provided Mr. Gautam Doshi confirmed that there are no material reasons for his resignation other than those mentioned in her resignation letter. Annexure B\"}],\"shareholding_snapshot\":{\"promoter_pct\":54.48,\"public_pct\":45.52,\"fii_pct\":14.53,\"dii_pct\":22.18,\"mf_pct\":12.84,\"institutional_pct\":36.71,\"noninst_pct\":8.81,\"mf_scheme_count\":49,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"Icici Prudential Value Fund\",\"shares\":89198583,\"pct\":3.72},{\"name\":\"Sbi Nifty 50 Etf\",\"shares\":56689578,\"pct\":2.36},{\"name\":\"Nippon Life India Trustee Ltd-A\/C Nippon India Large Cap Fund\",\"shares\":33125559,\"pct\":1.38}],\"period\":\"30-JUN-2026\",\"submission_date\":\"17-JUL-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1694893_17072026122439_WEB.xml\",\"previous_period\":\"31-MAR-2026\",\"previous_promoter_pct\":54.48,\"previous_fii_pct\":15.93,\"previous_dii_pct\":21.11,\"previous_mf_pct\":11.96,\"previous_institutional_pct\":37.04,\"previous_mf_scheme_count\":47,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null},\"bulk_block_deals\":[{\"deal_type\":\"Block\",\"date\":\"24 Jun, 2026\",\"party\":\"The Mtbj Ltd. As Trst For Govrnmnt Pension Invstmnt Fund Mutb400045794\",\"side\":\"Buy\",\"quantity\":\"154424\",\"price\":\"1,868\",\"source\":\"Public market-data page\",\"value\":\"\u20b928.85 Cr\"},{\"deal_type\":\"Block\",\"date\":\"24 Jun, 2026\",\"party\":\"The Mtbj Ltd. As Trst For Govrnmnt Pension Invstmnt Fund Mtbj400045828\",\"side\":\"Sell\",\"quantity\":\"154424\",\"price\":\"1,868\",\"source\":\"Public market-data page\",\"value\":\"\u20b928.85 Cr\"}]} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sun Pharmaceutical Industries in pre-market focus after board approves up to INR 10,000 crore NCD issuance, secures top credit ratings, and notes director.<\/p>\n","protected":false},"author":1,"featured_media":5711,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Sun Pharma in Focus After NCD Issuance Approval and Director Resignation | 14 October 2026","_witty_meta_description":"Sun Pharmaceutical Industries in pre-market focus after board approves up to INR 10,000 crore NCD issuance, secures top credit ratings, and notes director.","_witty_primary_phrase":"Sun Pharmaceutical Industries NCD issuance","_witty_reason_label":"NCD Issuance and Director Resignation","_witty_reason_confidence":"medium","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[199],"class_list":["post-5712","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-sunpharma"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/5712","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=5712"}],"version-history":[{"count":1,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/5712\/revisions"}],"predecessor-version":[{"id":5713,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/5712\/revisions\/5713"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/5711"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=5712"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=5712"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=5712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}